Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance - Report - MDSpire
Advertisement
Clinical Observation: Temporary Disease Management with Icotinib Following Osimertinib Resistance in Lung Adenocarcinoma with EGFR L858R/C797S and Absence of T790M
Clinical Report: Temporary Disease Management with Icotinib Following Osimertinib Resistance in Lung Adenocarcinoma with EGFR L858R/C797S and Absence of T790M
Background
Lung cancer is a leading cause of cancer-related mortality, with non-small cell lung cancer (NSCLC) representing a significant proportion of cases. EGFR mutations are prevalent in NSCLC, and osimertinib has become a standard treatment for patients with advanced EGFR-mutant NSCLC. However, resistance to osimertinib, particularly in the context of specific mutations like C797S, poses a challenge in treatment management.
Data Highlights
No numerical data or trial data available in the source material.
Key Findings
A 71-year-old woman with EGFR L858R lung adenocarcinoma developed resistance to osimertinib due to the C797S mutation.
Post-progression ctDNA analysis confirmed the presence of L858R/C797S without T790M.
The patient was treated with icotinib 125 mg tid after osimertinib failure.
Icotinib treatment resulted in stable disease for 6 months.
Clinical Implications
The case highlights the potential for first-generation EGFR-TKIs like icotinib to offer temporary disease control in patients with specific resistance mutations. Clinicians may consider molecular testing to guide treatment decisions in similar cases of osimertinib resistance.
Conclusion
This clinical observation underscores the need for tailored treatment strategies in patients with EGFR mutations who develop resistance to third-generation TKIs.
